

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A method for identifying a compound that modulates angiogenesis, the method comprising the steps of:
  - (i) contacting the compound with a cell expressing an ILKAP polypeptide, wherein the ILKAP polypeptide has at least 90% identity to an amino acid sequence of SEQ ID NO:2, and wherein the ILKAP polypeptide has an anti-angiogenic phenotype; and
  - (ii) determining the angiogenic or loss of angiogenesis phenotypic effect of the compound upon the cell expressing the ILKAP polypeptide, whereby a difference in the angiogenic or loss of angiogenesis effect as compared to the angiogenic or loss of angiogenesis effect in the absence of the compound indicates that the compound modulates angiogenesis.
- 2.-5. (Cancelled)
6. (Previously Presented) The method of claim 1, wherein the effect is determined by measuring phosphatase activity of the polypeptide.
- 7-13. (Cancelled)
14. (Original) The method of claim 1, wherein modulation is inhibition of angiogenesis.
15. (Original) The method of claim 1, wherein the polypeptide is recombinant.
16. (Original) The method of claim 1, wherein the polypeptide comprises a sequence of SEQ ID NO:2.
- 17-18. (Cancelled)

19. (Original) The method of claim 1, wherein the compound is a small organic molecule.

20-27. (Cancelled)

28. (Previously Presented) The method of claim 1, wherein the ILKAP polypeptide has at least 95% identity to an amino acid sequence of SEQ ID NO:2.

29. (Previously Presented) The method of claim 1, wherein the effect is measured using an assay selected from the group consisting of: avb3 expression, haptotaxis, and endothelial cell tube formation.